Search results for " Rheumatoid Arthritis"

showing 10 items of 42 documents

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

2018

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as a…

0301 basic medicineEvidence-based practiceImmunologyInflammationGuidelines as TopicSystemic lupus erythematosuBioinformaticsAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis;Autoimmune DiseaseAutoimmune DiseasesRheumatic Disease03 medical and health sciencesTherapeutic approachSystemic sclerosiEconomica0302 clinical medicineImmune systemSystemic lupus erythematosusAntiphospholipid syndromeEarly DiagnosiRheumatic DiseasesAntiphospholipid syndromemedicineImmunology and AllergyHumansRheumatoid arthritisRheumatoid arthritiAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis030203 arthritis & rheumatologySpondyloarthritidebusiness.industryBiomarkermedicine.diseaseClinical diseaseSjögren syndromeAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Autoimmune Diseases; Biomarkers; Early Diagnosis; Evidence-Based Practice; Guidelines as Topic; Humans; Rheumatic Diseases; Immunology and Allergy; ImmunologySettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisRheumatoid arthritisEvidence-Based PracticeBiomarker (medicine)SpondyloarthritidesSystemic sclerosismedicine.symptombusinessBiomarkersHuman
researchProduct

The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes

2018

Background Although in the past, prevention of the joint destruction and disability was strongly emphasised in Rheumatoid Arthritis (RA), at present, a growing body of evidence is focused at identifying the best management of associated comorbidities, such as Type 2 Diabetes (T2D). Recently, the hypothesis that blocking pro-inflammatory activity may be helpful in the treatment of some comorbidities has been proposed in RA patients. Objective We reviewed the role of IL-1β during RA and T2D, the efficacy of IL-1 blocking agents in controlling both diseases and, possible, decreasing the concomitant enhanced atherosclerotic process. Method After literature search, the available evidence has bee…

0301 basic medicineInterleukin-1betaInflammationAnakinra; Cardiovascular risk; Diabetes; IL-1β; Pathogenesis; Rheumatoid arthritis; Therapy; PharmacologyType 2 diabetesPathogenesisDiabeteProinflammatory cytokinePathogenesisArthritis Rheumatoid03 medical and health sciencesImmune systemPathogenesiDiabetes mellitusmedicineHumansRheumatoid arthritisRheumatoid arthritiPharmacologyAnakinrabusiness.industryDiabetesAntirheumatic AgentReceptors Interleukin-1General Medicinemedicine.diseaseCardiovascular riskSettore MED/16 - Reumatologia030104 developmental biologyAnakinraDiabetes Mellitus Type 2IL-1βRheumatoid arthritisAntirheumatic AgentsImmunologyTherapymedicine.symptombusinessmedicine.drugHuman
researchProduct

Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Ita…

2019

Background Rheumatoid arthritis (RA) is associated with an increased risk of morbidity and mortality, when compared with general population, largely due to enhanced atherosclerotic disease. In this work, we aimed at assessing both occurrence and predictive factors of subclinical and clinical atherosclerosis in RA. Methods From January 1, 2015, to December 31, 2015, consecutive participants with RA, admitted to Italian Rheumatology Units, were assessed in the GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort. After that, those participants were followed up in a 3-year, prospective, observational study, assessing the occurrence of subclinical and clinical ather…

0301 basic medicineMaleTime Factorslcsh:Diseases of the musculoskeletal systemType 2 diabetesComorbidityArthritis Rheumatoid0302 clinical medicineProspective StudiesSubclinical infectionAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceAge FactorsType 2 diabetesMiddle AgedPrognosisCardiovascular diseaseSurvival RateCardiovascular diseasesItalyRheumatoid arthritisAtherosclerosiCohortDisease ProgressionFemaleResearch ArticleAdultmedicine.medical_specialtyRemissionPopulation03 medical and health sciencesYoung AdultAge DistributionSex FactorsInternal medicinemedicineHumansSex DistributionRheumatoid arthritiseducationRheumatoid arthritiAged030203 arthritis & rheumatologybusiness.industryAtherosclerosis; Cardiovascular diseases; Remission; Rheumatoid arthritis; Type 2 diabetesmedicine.diseaseAtherosclerosisRheumatologySettore MED/16 - Reumatologia030104 developmental biologyBlood pressurelcsh:RC925-935businessFollow-Up Studies
researchProduct

Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with…

2015

The aim of this study was to assess safety and efficacy of ultrasonography (US)-guided intra-articular injections using tumor necrosis factor (TNF) blockers compared to corticosteroids in rheumatoid arthritis (RA) or psoriatic arthritis (PsA) patients, experiencing refractory monoarthritis despite the current systemic therapy. Eighty-two patients were randomized to receive three intra-articular injections monthly of either corticosteroid or TNF blockers. Primary endpoints were the safety and an improvement greater than 20% for visual analogic scales of involved joint pain in patients injected with anti-TNFα. Further clinical, US, and magnetic resonance imaging (MRI) evaluations were consid…

0301 basic medicineMalerheumatoid arthritispsoriatic arthritimagnetic resonance imaging (MRI)anti-tumor necrosis factor α agent; intra-articular injection; magnetic resonance imaging (MRI); psoriatic arthritis; rheumatoid arthritis; treat-to-target strategy; ultrasonography; Pharmacology; Immunology; Immunology and AllergyInflammatory arthritisAnti-Inflammatory Agentsanti-tumor necrosis factor α agentInjections Intra-ArticularArthritis Rheumatoid0302 clinical medicineAdrenal Cortex HormonesImmunology and Allergyintra-articular injectionpsoriatic arthritismedicine.diagnostic_testultrasonographyMiddle AgedArthralgiaRheumatoid arthritisJoint painAntirheumatic AgentsCorticosteroidTumor necrosis factor alphaFemalemedicine.symptomAdultmedicine.medical_specialtymedicine.drug_classImmunology03 medical and health sciencesPsoriatic arthritisInternal medicineMonoarthritismedicineHumansImmunologic FactorsAged030203 arthritis & rheumatologyPharmacologybusiness.industryTumor Necrosis Factor-alphaArthritis PsoriaticMagnetic resonance imagingOriginal Articlesrheumatoid arthritimedicine.diseaseSurgerytreat-to-target strategy030104 developmental biologybusiness
researchProduct

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (r…

2017

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to th…

0301 basic medicineQuality managementEffectivenesslaw.inventionSystemic sclerosi0302 clinical medicineAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Immunology and Allergy; ImmunologylawAntiphospholipid syndromeImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSSpondyloarthritideClinical Trials as TopicEffectiveneDisease ManagementQuality Improvement3. Good healthSjogren's syndromeRheumatoid arthritis[SDV.IMM]Life Sciences [q-bio]/ImmunologySystemic sclerosisUnmet needmedicine.medical_specialtyRemissionImmunologyAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs;Systemic lupus erythematosuUnmet needs; rheumatoid arthritis; spondyloarthritides;Unmet needsNOAutoimmune Diseases03 medical and health sciencesSystemic lupus erythematosusAntiphospholipid syndromeInternal medicineRheumatic DiseasesmedicineHumansRheumatoid arthritisIntensive care medicineRheumatoid arthriti030203 arthritis & rheumatologyAutoimmune diseasetherapybusiness.industryAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Autoimmune Diseases; Clinical Trials as Topic; Disease Management; Humans; Quality Improvement; Rheumatic Diseases; Immunology and Allergy; Immunologymedicine.diseaseRheumatologyBiologic drugs treatment030104 developmental biologyautoimmune rheumatic diseasesPhysical therapyCLARITYSpondyloarthritidesbusinessWorking group
researchProduct

IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?

2016

ABSTRACT: Although in the past the prevention of joint destruction in rheumatoid arthritis (RA) was strongly emphasized, now a great interest is focused on associated comorbidities in these patients. Multiple data suggest that a large percentage of RA patients are affected by Type 2 Diabetes (T2D), whose incidence has reached epidemic levels in recent years, thus increasing the health care costs. A better knowledge about the pathogenesis of these diseases as well as the mechanisms of action of drugs may allow both policy designers and physicians to choose the most effective treatments, thus lowering the costs. This review will focus on the role of Interleukin (IL)-1β in the pathogenesis of …

0301 basic medicinemedicine.medical_specialtyIL-1 blocking agentpathogenesimedicine.medical_treatmentInterleukin-1betaImmunologyType 2 diabetesComorbiditymacrophagePathogenesisArthritis Rheumatoid03 medical and health sciencesHealth careMedicineAnimalsHumansImmunology and AllergyRheumatoid arthritisIntensive care medicineAntibodies BlockingRheumatoid arthrititype 2 diabetebusiness.industryIL-1 blocking agentsIncidence (epidemiology)pathogenesisInterleukinImmunotherapybiologic drug; IL-1 blocking agents; IL-1β; macrophage; pathogenesis; Rheumatoid arthritis; type 2 diabetes; Immunology and Allergy; Immunologymedicine.diseaseComorbiditySettore MED/16 - Reumatologia030104 developmental biologyDiabetes Mellitus Type 2IL-1βRheumatoid arthritisImmunologyImmunotherapytype 2 diabetesbusinessbiologic drug
researchProduct

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

2021

International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in ch…

0301 basic medicinerheumatoid arthritismedicine.medical_specialtyantiphospholipid syndrome; precision medicine; primary sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosis; consensus; humans; precision medicine; autoimmune diseases; lupus erythematosus systemic; sjogren's syndromeConsensusspondyloarthritidesystemic sclerosisImmunologysystemic lupus erythematosuSjogren's Syndrome.Context (language use)Consensuprimary Sjogren's syndromeAutoimmune DiseaseTreatment failureAutoimmune DiseasesNOEfficacy03 medical and health sciences0302 clinical medicineprimary Sjogren’s syndromeAcquired immunodeficiency syndrome (AIDS)systemic lupus erythematosusmedicineImmunology and AllergyHumansLupus Erythematosus SystemicIn patientIntensive care medicineAdverse effect030203 arthritis & rheumatologybusiness.industryPrecision medicinePrecision medicine; antiphospholipid syndrome; primary Sjogren’s syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisEnvironmental exposurerheumatoid arthritimedicine.diseasePrecision medicineantiphospholipid syndrome; Precision medicine; primary Sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisspondyloarthritides3. Good health030104 developmental biologySjogren's Syndrome[SDV.IMM]Life Sciences [q-bio]/Immunologybusinesssystemic sclerosiantiphospholipid syndromeHuman
researchProduct

Interleukin-9 and T helper type 9 cells in rheumatic diseases

2016

Summary Interleukin (IL)-9 is a 28-30 kDa monomeric glycosylated polypeptide belonging to the IL-7/IL-9 family of proteins that bind to a composite receptor consisting of the private receptor IL-9R and the IL-2 receptor, gamma (IL-2RG), a common gamma subunit shared by the receptors of many different cytokines. The IL-9R is expressed widely and IL-9 impacts a number of effector cells, such as effector T cells, B cells, innate lymphoid cells, mast cells, polymorphonuclear cells, epithelial cells and smooth muscle cells, playing an important role in regulating inflammatory immunity. The critical role of IL-9 in promoting cellular and humoral immune responses makes it an important focus of pot…

0301 basic medicinerheumatoid arthritispsoriatic arthritisystemic sclerosisSLEReview ArticleIL-9; psoriatic arthritis; rheumatoid arthritis; SLE; systemic sclerosis; Th9 cells; vasculitis; Immunology and Allergy; ImmunologyTh9 cellsvasculitisArthritis RheumatoidInterleukin 210302 clinical medicineT-Lymphocyte SubsetsTh9 cellIL-9; SLE; Th9 cells; psoriatic arthritis; rheumatoid arthritis; systemic sclerosis; vasculitisLupus Erythematosus SystemicMedicineImmunology and AllergyIL-2 receptorpsoriatic arthritisB-LymphocytesInterleukin-17Innate lymphoid cellT-Lymphocytes Helper-InducerAcquired immune systemInterleukin 10vasculitiInterleukin 12systemic sclerosiSignal TransductionImmunologyAutoimmune Diseases03 medical and health sciencesRheumatic DiseasesAnimalsHumans030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryArthritis PsoriaticInterleukin-9rheumatoid arthritiIL-9Immunity HumoralInterleukin 33Settore MED/16 - Reumatologia030104 developmental biologyCTLA-4Immunologybusiness
researchProduct

Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

2008

The prevalence of concurrent rheumatoid arthritis (RA) and hepatitis C virus (HCV) infection is probably underestimated because of the increasing spread of this virus worldwide, especially in developing countries. In these patients, anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy may aggravate hepatitis and increase viremia. We evaluated the safety of these treatments, which remain controversial.Thirty-one HCV-positive patients (23 women, 8 men, mean age 59+/-13 yrs, mean disease duration 13+/-11.5 SD yrs) with active RA [Disease Activity Score 28 (DAS28)3.2] unresponsive to conventional therapies were treated with TNF-alpha blockers (infliximab 11, etanercept 17, adalimumab 3) at…

AdultAged 80 and overMalerheumatoid arthritissafetyhepatitis c virus; rheumatoid arthritis; safety; tumor necrosis factor-α blockerTumor Necrosis Factor-alphaAdalimumabHepatitis C ChronicMiddle AgedViral Loadhepatitis c virusInfliximabEtanerceptArthritis Rheumatoidtumor necrosis factor-α blockerAdalimumab Etanercept InfliximabAntirheumatic AgentsHumansFemaleanti-tumor necrosis factor-alpha; rheumatoid arthritis; hepatitis CAgedFollow-Up StudiesRetrospective Studies
researchProduct

Downregulation of miRNA17-92 cluster marks Vγ9Vδ2 T cells from patients with rheumatoid arthritis

2018

Abstract Background We aimed to evaluate the phenotype, function, and microRNA (miRNA)17–92 cluster expression in Vγ9Vδ2 T-cell subsets and the correlation with immune response in rheumatoid arthritis (RA) patients. Methods Peripheral blood from 10 early RA untreated patients and 10 healthy donors (HD) was obtained. Polyclonal Vγ9Vδ2 T-cell lines were generated and analysed by flow cytometry. Analysis of miRNA17–92 cluster expression was performed by real-time polymerase chain reaction (RT-PCR), and expression of mRNA target genes was also studied. Results A remarkable change in the distribution of Vγ9Vδ2 T-cell functional subsets was observed in the peripheral blood of RA patients compared…

AdultMale0301 basic medicinemiRNA17–92lcsh:Diseases of the musculoskeletal systemInflammatory cytokineImmunologyDown-RegulationBiologyγδ T cellsProinflammatory cytokineFlow cytometryArthritis RheumatoidPathogenesis03 medical and health sciences0302 clinical medicineImmune systemRheumatologyT-Lymphocyte SubsetsInflammatory cytokines; miRNA17-92; Rheumatoid arthritis; γδ T cells; Rheumatology; Immunology and Allergy; ImmunologymicroRNAmedicineHumansImmunology and AllergyRheumatoid arthritisRheumatoid arthritiγδ T cellmedicine.diagnostic_testEffectorInterleukinMiddle AgedInflammatory cytokinesPhenotypemiRNA17-92MicroRNAsSettore MED/16 - Reumatologia030104 developmental biology030220 oncology & carcinogenesisImmunologyFemalelcsh:RC925-935Research Article
researchProduct